StreetInsider.com News Articles

Form EFFECT NewcelX Ltd.

Thu, 27 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260827/26984186.html

Form EFFECT NewcelX Ltd.

Thu, 27 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260827/26984186.html

Form D NewcelX Ltd.

Mon, 24 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26968109.html

Form D NewcelX Ltd.

Mon, 24 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26968109.html

Form F-3 NewcelX Ltd.

Thu, 20 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26956402.html

Form F-3 NewcelX Ltd.

Thu, 20 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26956402.html

Form 6-K NewcelX Ltd. For: Aug 03

Mon, 03 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260803/26858438.html

Form 6-K NewcelX Ltd. For: Aug 03

Mon, 03 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260803/26858438.html

Form 6-K NewcelX Ltd. For: Jul 31

Fri, 31 Jul 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260731/26847682.html

Form 6-K NewcelX Ltd. For: Jul 31

Fri, 31 Jul 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260731/26847682.html

NewcelX prices $1.4M private placement at 20% premium to market

Fri, 31 Jul 2026 09:00:54 -0400

NewcelX Ltd. (NASDAQ: NCEL), a clinical-stage biopharmaceutical company based in Zurich, announced it has entered into securities purchase agreements for a private placement totaling approximately $1.4 million, priced at $4.033 per share — a 20% premium to the company's closing price on July 30, 2026.

Under the terms of the agreements, NewcelX is selling 347,134 common shares along with warrants to purchase an additional 347,134 common shares at an exercise price of $4.437 per share, representing 132% of the July 30 closing price. The offering includes participation from existing shareholders as well as new investors and is expected to close on

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

Fri, 31 Jul 2026 09:00:00 -0400

Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting

ZURICH, Switzerland, July 31, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $4.033 per share, representing a 20% premium to the last closing price of the Company’s common shares on July 30, 2026.

Pursuant to the terms of the securities purchase agreements, the Company is

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

Fri, 31 Jul 2026 09:00:00 -0400

Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting

Pursuant to the terms of the securities purchase agreements, the Company is

Form 6-K NewcelX Ltd. For: Jul 15

Wed, 15 Jul 2026 09:42:00 -0400

si-local-file:///var/storage/secattach/20260715/26772163.html

Form 6-K NewcelX Ltd. For: Jul 15

Wed, 15 Jul 2026 09:42:00 -0400

si-local-file:///var/storage/secattach/20260715/26772163.html

Laidlaw Starts NewcelX AG (NCEL) at Buy

Mon, 13 Jul 2026 03:52:35 -0400

Laidlaw analyst Yale Jen initiates coverage on NewcelX AG (NASDAQ: NCEL) with a Buy rating and a price target of $23.00.

The analyst comments: “NCEL is an early clinical stage biotech company focusing on developing cell therapies with NCEL-101 as lead product. NCEL-101 is a novel pluripotent stem cells (PSCs)-derived islet-like clusters (ILC), and along with tegoprubart, a novel immunosuppressant developed by Eledon Pharmaceuticals as an islet cell transplant (ICT) – a potential curative treatment for type 1 diabetes (T1D). A Phase I/IIa study potentially could start in 1H27 with initial clinical data potentially available in 2H27 or 2028. If ultimately

Laidlaw Starts NewcelX AG (NCEL) at Buy

Mon, 13 Jul 2026 03:52:35 -0400

Laidlaw analyst Yale Jen initiates coverage on NewcelX AG (NASDAQ: NCEL) with a Buy rating and a price target of $23.00.

NewcelX adds diabetes researcher Dr. Camillo Ricordi to advisory board

Wed, 08 Jul 2026 09:15:14 -0400

NewcelX Ltd. (Nasdaq: NCEL) has appointed Camillo Ricordi, M.D., to its Scientific Advisory Board, the clinical-stage biotechnology company announced July 8, 2026.

Dr. Ricordi holds positions at the University of Miami Miller School of Medicine, where he has served as Professor of Surgery, Distinguished Professor of Medicine, and Professor of Biomedical Engineering, Microbiology and Immunology since 1993. He also serves as Chief of the Division of Cellular Transplantation, Director of the Cell Transplant and NABTU Regenerative Medicine Center, and Director Emeritus of the Diabetes Research Institute. He has authored more than 1,250 publications with over 64,000 citations and holds an h-index

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

Wed, 08 Jul 2026 09:15:00 -0400

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials

Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals

ZURICH, July 08, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biotechnology company developing regenerative cell therapies for type 1 diabetes and other serious diseases, today announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board.

Dr. Ricordi is internationally recognized as one of the world's foremost

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

Wed, 08 Jul 2026 09:15:00 -0400

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials

Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals

Dr. Ricordi is internationally recognized as one of the world's foremost

Form 6-K NewcelX Ltd. For: Jul 08

Wed, 08 Jul 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260708/26745388.html

Form 6-K NewcelX Ltd. For: Jul 08

Wed, 08 Jul 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260708/26745388.html

NewcelX gets FDA feedback supporting NCEL-101 diabetes trial path

Wed, 01 Jul 2026 09:30:17 -0400

NewcelX Ltd. (Nasdaq: NCEL) announced it has completed a Type B Pre-IND meeting with the U.S. Food and Drug Administration, receiving feedback that supports the company's proposed development strategy for NCEL-101, its stem cell-derived islet product candidate for type 1 diabetes.

The FDA provided favorable feedback on NewcelX's Chemistry, Manufacturing, and Controls processes and preclinical program, allowing the company to proceed toward Investigational New Drug enabling activities. The planned clinical trial would combine NCEL-101 with tegoprubart, an investigational anti-CD40L antibody developed by Eledon Pharmaceuticals (Nasdaq: ELDN).

Ronen Twito, CEO and Executive Chairman of NewcelX, said: "Coming out of our FDA meeting, we

NewcelX gets FDA feedback supporting NCEL-101 diabetes trial path

Wed, 01 Jul 2026 09:30:17 -0400

Ronen Twito, CEO and Executive Chairman of NewcelX, said: "Coming out of our FDA meeting, we

Form 6-K NewcelX Ltd. For: Jul 01

Wed, 01 Jul 2026 09:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26718077.html